Compare ING Groep NV (ING) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Smith & Nephew plc — how do they compare? ING Groep NV trades at $33.15 (market cap $96.81B), while Smith & Nephew plc trades at $27.21 (market cap $11.31B). The key difference: ING Groep NV is far larger — about 8.6× Smith & Nephew plc's market cap, and ING Groep NV pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and Smith & Nephew plc for 120 Days on average.
| ING | SNN | |
|---|---|---|
Market Cap | $96.81B | $11.31B |
Volume | 2,635,505 | 1,050,005 |
Sector | Financials | Health |
52-Week High | $37.27 | $37.17 |
52-Week Low | $23.66 | $26.42 |
Typical Hold Time | 93 Days | 120 Days |
Enterprise Value | $236.31B | $14.35B |
Dividend Yield | 3.9% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.43, down 4.21% with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters with Q2 2026 EPS of $0.79 versus $0.75 expected. Revenue growth remains steady at $22.9B in 2025 with a robust 28.34% net margin. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations.
The stock presents a value opportunity with a reasonable P/E of 13.09 and strong profitability metrics, though negative cash flow trends and regulatory challenges in Australia warrant monitoring. Management's raised ROE target above 16% for 2027 signals confidence in continued operational improvement and strategic execution.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
